A comparison of the effects of intravenous pentagastrin on patients with social phobia, panic disorder and healthy controls

Neuropsychopharmacology

Volumn 16, Issue 3, 1997, Pages 229-237

  McCann, Una D ^a,c   Slate, Shiyoko O ^a   Geraci, Mariila ^a   Roscow Terrill, Diana ^a   Uhde, Thomas W ^b  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Biological Psychiatry Branch   (United States)

Author keywords

CCK; chemical models; panic; social interaction

Indexed keywords

HYDROCORTISONE; PENTAGASTRIN; PLACEBO;

ADULT; ANXIETY; ARTICLE; BEHAVIOR; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PANIC; PRIORITY JOURNAL; SOCIAL PHOBIA;

EID: 0031106329     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(96)00197-2     Document Type: Article

References (26)

1. Abelson JL, Nesse RM (1994): Pentagastrin infusions in patients with panic disorder I. Symptoms and Cardiovascular Responses. Biol Psychiatry 36:73-83
2. Abelson JL, Nesse RM, Vinik AI (1994): Pentagastrin infusions in patients with panic disorder II. Neuroendocrinology. Biol Psychiatry 36:84-96
3. Bradwejn J, Koszycki D, Meterissian (1990): Cholecystokinin-tetrapeptide induced panic attacks in panic disorder. Can J Psychiatry 35:83-85
4. Bradwejn J, Koszycki D, Bourin M (1991a): Dose ranging study of the effect of CCK-4 in healthy volunteers. J Psychiatr Neurosci 16(2):91-95
5. Bradwejn J, Koszycki D, Payeur R (1991b): Enhanced sensitivity to cholecystokinin-tetrapeptide in panic disorder: Clinical and behavioral findings. Arch Gen Psychiatry 48:603-610.
6. Crawley JN (1985): Comparative distribution of cholecystokinin and other neuropeptides. Ann NY Acad Sci 448:1-8
7. Ervin FR, Palmour RM, Bradwejn J (1991): A new primate model for panic disorder. Biol Psychiatry 29:430S.
8. Fekete M, Lengyel A, Hegedus B, Penke B, Zarandy M, Toth GK, Telegdy G (1984): Further analysis of the effects of cholecystokinin octapeptide on avoidance in rats. Eur J Pharmacol 98:79-91
9. Fyer AJ, Mannuzza S, Gallops MS, Martin LY (1990): Familial transmission of simple phobias and fears: A preliminary report. Arch Psychiatry 47:252-256
10. Fyer AJ, Mannuzza S, Chapman TF, Liebowitz MR, Klein DF (1993): A direct interview family study of social phobia. Arch Gen Psychiatry 50:286-293
11. Harro J, Vasar E (1991): Evidence that CCK-B receptors mediate the regulation of exploratory behavior in the rat. Eur J Pharmacol 193:379-381
12. Harro J, Vasar E, Bradwejn J (1993): Cholecystokinin in animal and human research on anxiety. Trends Pharmacol Sci 14:244-249
13. Kendler K, Neale M, Kessler R, Heath AC, Eaves LJ (1992): The genetic epidemiology of phobias in women: The interrelationship of agoraphobia, social phobia, situational phobia and simple phobia. Arch Gen Psychiatry 49:273-281
14. Kessler RC, McGonagle DK, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen HU, Kendler KS (1994): Lifetime and 12-month prevalence of DSM-III-R psychiatric disorder in the United States: Results from the National Comorbidity Survey. Arch Gen Psychiatry 51:8-19
15. Kendler KS, Walters EE, Neale MC, Kessler RC, et al. (1995): The structure of the genetic and environmental risk factors for six major psychiatric disorders in women. Phobias, Generalized anxiety disorder, panic disorder, bulimia, major depression and alcoholism. Arch Gen Psychiatry 52(5):374-83
16. Liebowitz MR, Fyer AJ, Gorman JM, Dillon D, Davies S, Stein JM, Cohen BS, Klein DF (1985): Specificity of lactate infusions in social phobia versus panic disorders. Am J Psychiatry 142(8): 947-949
17. McCann UD, Slate SO, Geraci M, Uhde TW (1995): Peptides and anxiety: A dose response evaluation of pentagastrin in healthy volunteers. Anxiety 1:258-267
18. Regier DA, Boyd JH, Burke JD, Rae DS, Myers JK, Kramer M, Robins LN, George LK, Karno M, Locke BZ (1988): One-month prevalence of mental disorders in the United States: Based on five Epidemiologic Catchment Area sites. Arch Gen Psychiatry 45:977-986
19. Schleyer B, Aarons C, Mannuzza S, Martin L, Fyer AJ (1990): Schedule for Affective Disorders and Schizophrenia Lifetime Version Modified for the Study of Anxiety Disorders (Updated for DSM-III-R).
20. Speilberger CD, Gorsuch RW, Lushene RE (1970): State-Trait Anxiety Inventory. Palo Alto, CA, consulting Psychologists Press, Inc.
21. Tancer ME, Stein MB, Uhde TW (1991): Lactate response to caffeine in panic disorder: A replication using an "anxious" control group. Biol Psychiatry 29:57
22. Tancer ME, Stein MB, Uhde TW (1994): Growth hormone response to intravenous clonidine in social phobia: Comparison to patients with panic disorder and healthy volunteers. Biol Psychiatry 34:252-256
23. Uhde TW (1990): Caffeine provocation of panic: A focus on biological mechanisms. In Ballenger JC (ed), Neurobiology of Panic Disorder, Frontiers in Clinical Neuroscience, vol. 8. New York, Alan R Liss
24. Uhde TW, Tancer ME, Black B, Brown TM (1991): Phenomenology and neurobiology of social phobia: Comparison with panic disorder. J Clin Psychiatry 52(11, suppl):31-40
25. van Megen HJGM, Westenberg HGM, den Boer JA, Haigh JRM, Traub M (1994): Pentagastrin induced panic attacks: Enhanced sensitivity in panic disorder patients. Psychopharmacology 114:449-455
26. Zung WWK (1971): A rating instrument for Anxiety Disorders. Psychosomatics 12:371-379